Long-term consequences of polycystic ovary syndrome on cardiovascular risk

Fertility and Sterility

Volumn 91, Issue 4 SUPPL., 2009, Pages 1563-1567

  Rizzo, Manfredi ^a   Berneis, Kaspar ^b   Spinas, Giatgen ^b   Rini, Giovam Battista ^a   Carmina, Enrico ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

cardiovascular risk; events; menopause; Polycystic ovary syndrome

Indexed keywords

ADIPONECTIN; ANDROGEN; C REACTIVE PROTEIN; ENDOTHELIN 1; HOMOCYSTEINE; PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ANDROGEN RELEASE; ARTICLE; ATHEROSCLEROSIS; BODY WEIGHT; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; HYPERANDROGENISM; MORBIDITY; OBESITY; OVARY POLYCYSTIC DISEASE; POSTMENOPAUSE; PRIORITY JOURNAL; STROKE;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; AGING; ANDROGENS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; FEMALE; HUMANS; HYPERANDROGENISM; MIDDLE AGED; OBESITY; POLYCYSTIC OVARY SYNDROME; RISK FACTORS;

EID: 63249124743     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2008.09.070     Document Type: Article

References (48)

1. Guzick D.S. Cardiovascular risk in PCOS. J Clin Endocrinol Metab 89 (2004) 3694-3695
2. Lobo R.A., and Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 132 (2000) 989-993
3. Legro R.S. Polycystic ovary syndrome and cardiovascular disease: a premature association?. Endocr Rev 24 (2003) 302-312
4. Kelly C.C., Lyall H., Petrie J.R., Gould G.W., Connell J.M., and Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86 (2001) 2453-2455
5. Boulman N., Boulman N., Levy Y., Leiba R., Shachar S., Linn R., et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 89 (2004) 2160-2165
6. Möhlig M., Spranger J., Osterhoff M., Ristow M., Pfeiffer A.F., Schill T., et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 150 (2004) 525-532
7. Panidis D., Kourtis A., Farmakiotis D., Mouslech T., Rousso D., and Koliakos G. Serum adiponectin levels in women with polycystic ovary syndrome. Hum Reprod 18 (2003) 1790-1796
8. Spranger J., Möhlig M., Wegewitz U., Ristow M., Pfeiffer A.F., Schill T., et al. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol 61 (2004) 738-746
9. Sampson M., Kong C., Patel A., Unwin R., and Jacobs H.S. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol 45 (1996) 623-629
10. Dahlgren E., Janson P.O., Johansson S., Lapidus L., Lindstedt G., and Tengborn L. Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil Steril 61 (1994) 455-460
11. Diamanti-Kandarakis E., Spina G., Kouli C., and Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 86 (2001) 4666-4673
12. Loverro G., Lorusso F., Mei L., Depalo R., Cormio G., and Selvaggi L. The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol Obstet Invest 53 (2002) 157-162
13. Sabuncu T., Vural H., and Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem 34 (2001) 407-413
14. Cussons A.J., Stuckey B.G., and Watts G.F. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 185 (2006) 227-239
15. Legro R.S., Kunselman A.R., and Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 111 (2001) 607-613
16. Berneis K., Rizzo M., Fruzzetti F., Lazzaroni V., and Carmina E. Atherogenic lipoprotein phenotype and LDL size and subclasses in women with polycystic ovary syndrome. J Clin Endocrinol Metab 92 (2007) 186-189
17. Valkenburg O., Steegers-Theunissen R.P., Smedts H.P., Dallinga-Thie G.M., Fauser B.C., Westerveld E.H., et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab 93 (2008) 470-476
18. Berneis K., Rizzo M., Hersberger M., Rini G.B., Di Fede G., Pepe I., Spinas G.A., and Carmina E. Atherogenic forms of dyslipidemia in women with polycystic ovary syndrome. Int J Clin Pract (2008) In press
19. Rizzo M., and Berneis K. Low-density-lipoproteins size and cardiovascular risk assessment. [published correction appears in QJM 2007;100:147]. QJM 99 (2006) 1-14
20. Tíras M.B., Yalcìn R., Noyan V., Maral I., Yìldìrìm M., Dörtlemez O., et al. Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome. Hum Reprod 14 (1999) 1949-1952
21. Orio F., Palomba S., Spinellli L., Cascella T., Tauchmanova L., Zullo F., et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 89 (2004) 3696-3701
22. Kelly C.J., Speirs A., Gould G.W., Petrie J.R., Lyall H., and Connell J.M. Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 87 (2002) 742-746
23. Lakhani K., Constantinovici N., Purcell W.M., Fernando R., and Hardiman P. Internal carotid artery haemodynamics in women with polycystic ovaries. Clin Sci (Lond) 98 (2000) 661-665
24. Tarkun I., Arslan B.C., Cantürk Z., Türemen E., Sahin T., and Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 89 (2004) 5592-5596
25. Orio Jr. F., Palomba S., Cascella T., De Simone B., Di Biase S., Russo T., et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 4588-4593
26. Kravariti M., Naka K.K., Kalantaridou S.N., Kazakos N., Katsouras C.S., Makrigiannakis A., et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 5088-5095
27. Diamanti-Kandarakis E., Alexandraki K., Protogerou A., Piperi C., Papamichael C., Aessopos A., et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol 152 (2005) 749-756
28. Carmina E., Orio F., Palomba S., Longo R.A., Cascella T., Colao A., et al. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med 119 (2006) 356 e1-6
29. Talbott E.O., Guzick D.S., Sutton-Tyrrell K., McHugh-Pemu K., Zborowski J., Remsberg K., et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 20 (2000) 2414-2421
30. Guzick D.S., Talbott E.O., Sutton-Tyrrell K., Herzog H.C., Kuller L.H., and Wolfson Jr. S.K. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol 174 (1996) 1224-1229
31. Talbott E.O., Zborowski J.V., Rager J.R., Boudreaux M.Y., Edmundowicz D.A., and Guzick D.S. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 5454-5461
32. Christian R.C., Dumesic D.A., Behrenbeck T., Oberg A., Sheedy P.F., and Fitzpatrick L. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88 (2003) 2562-2568
33. Birdsall M.A., Farquhar C.M., and White H.D. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 126 (1997) 32-35
34. Labrie F., Belanger A., Cusan L., Gomez J., and Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J Clin Endocrinol Metab 82 (1997) 2396-2402
35. Bili H., Laven J., Imani B., Eijkemans M.J., and Fauser B.C. Age-related differences in features associated with polycystic ovary syndrome in normogonadotrophic oligo-amenhorroeic infertile women of reproductive years. Eur J Endocrinol 145 (2001) 749-755
36. Koivunen R., Laatikainen T., Tomas C., Huhtaniemi I., Tapanainen J., and Martikainen H. The prevalence of polycystic ovaries in healthy women. Acta Obstet Gynecol Scand 78 (1999) 137-141
37. Elting M.W., Korsen T.J., Rekers-Mombarg L.T., and Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod 15 (2000) 24-28
38. Vulpoi C., Lecomte C., Guilloteau D., and Lecomte P. Ageing and reproduction: is polycystic ovary syndrome an exception?. Ann. Endocrinol (Paris) 68 (2007) 45-50
39. Shaw LJ, Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, et al. Post-menopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health National Heart, Lung, and Blood Institute (NHLBI) Sponsored Women's Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab. Published online January 8, 2008.
40. Dahlgren E., Johansson S., Lindstet G., Knutsson F., Oden A., Janson P.O., et al. Women with polycystic ovary syndrome wedge resected in 1956-1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 57 (1992) 505-513
41. Dahlgren E., Janson P.O., Johansson S., Lapidus L., and Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 71 (1992) 599-604
42. Pierpoint T., McKeigue P.M., Isaacs A.J., Wild S.H., and Jacobs H.S. Mortality of woman with polycystic ovary syndrome at long term follow up. J Clin Epidemiol 51 (1998) 581-586
43. Wild S.H., Pierpoint T., Mckeigue P.M., and Jacobs H.S. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol 52 (2000) 595-600
44. Dawber T.R., Meadors G.F., and Moore Jr. F.E. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health 41 (1951) 279-281
45. Cibula D., Cifkova R., Fanta M., Poledne R., Zivny J., and Skibova J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 15 (2000) 785-789
46. Elting M.W., Korsen T.J., Bezemer P.D., and Schoemaker J. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod 16 (2001) 556-560
47. Talbott E.O., Zborowski J.V., Sutton-Tyrrell K., McHugh-Pemu K.P., and Guzick D.S. Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Am 28 (2001) 111-133
48. Krentz A.J., von Mühlen D., and Barrett-Connor E. Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease. Menopause 14 (2007) 284-292